The reversible phosphorolysis of purine and pyrimidine nucleosides is an important biochemical reaction in the salvage pathway, which provides an alternative to the de no o purine and pyrimidine biosynthetic pathways. Structural studies in our laboratory and by others have revealed that only two folds exist that catalyse the phosphorolysis of all nucleosides, and provide the basis for defining two families of nucleoside phosphorylases. The first family (nucleoside phosphorylase-I) includes enzymes that share a common single-domain subunit, with either a trimeric or a hexameric quaternary structure, and accept a range of both purine and pyrimidine nucleoside substrates. Despite differences in substrate specificity, amino acid sequence and quaternary structure, all members of this family share a characteristic subunit topology. We have also carried out a sequence motif study that identified regions of the common subunit fold that are functionally significant in differentiating the various members of the nucleoside phosphorylase-I family. Although the substrate-binding sites are arranged similarly for all members of the nucleoside phosphorylase-I family, a comparison of the active sites from the known structures of this family indicates significant differences between the trimeric and hexameric family members. Sequence comparisons also suggest structural identity between the nucleoside phosphorylase-I family and both 5h-methylthioadenosine\ S-adenosylhomocysteine nucleosidase and AMP nucleosidase. Members of the second family of nucleoside phosphorylases (nucleoside phosphorylase-II) share a common two-domain
INTRODUCTION TO THE NUCLEOSIDE PHOSPHORYLASES
Biochemical processes involving nucleotides and nucleotide precursors are some of the most ubiquitous and fundamental in the function and survival of the cell. One such biochemical reaction that has been studied for many years is the phosphorolysis of purine and pyrimidine nucleosides, whereby the C-N glycosidic bond is cleaved by a phosphate ion to yield the free base and ribose 1-phosphate. The enzymic cleavage of the glycosidic bond in purine and pyrimidine ribosides was first noted by Levene [1] , even before the detailed structure of nucleic acids was fully understood. The discovery of the enzyme responsible for this cleavage has been attributed to Levene and Medigreceanu [2] . Later, in 1924, Levene and co-workers published two papers on the general properties [3] and purification methods [4] of nucleosidase, as the enzyme had come to be called. Additional studies confirmed the enzymic cleavage of the glycosidic bonds in pyrimidines [5, 6] and demonstrated the existence of two separate Abbreviations used : AnPRT, anthranilate phosphoribosyltransferase ; MTA/SAH, 5h-methylthioadenosine/S-adenosylhomocysteine ; MTAP, 5h-deoxy5h-methylthioadenosine phosphorylase ; hMTAP, human MTAP ; NP-I, nucleoside phosphorylase-I ; NP-II, nucleoside phosphorylase-II ; PNP, purine nucleoside phosphorylase ; bPNP, bovine PNP ; hPNP, human PNP ; PyNP, pyrimidine nucleoside phosphorylase ; TP, thymidine phosphorylase ; UP, uridine phosphorylase. 1 To whom correspondence should be addressed (e-mail see3!cornell.edu).
subunit fold and a dimeric quaternary structure, share a significant level of sequence identity ( 30 %) and are specific for pyrimidine nucleosides. Members of this second family accept both thymidine and uridine substrates in lower organisms, but are specific for thymidine in mammals and other higher organisms. A possible relationship between nucleoside phosphorylase-II and anthranilate phosphoribosyltransferase has been identified through sequence comparisons. Initial studies in our laboratory suggested that members of the nucleoside phosphorylase-II family require significant domain movements in order for catalysis to proceed. A series of recent structures has confirmed our hypothesis and provided details of these conformational changes. Structural studies of the nucleoside phosphorylases have resulted in a wealth of information that begins to address fundamental biological questions, such as how Nature makes use of the intricate relationships between structure and function, and how biological processes have evolved over time. In addition, the therapeutic potential of suppressing the nucleoside phosphorylase activity in either family of enzymes has motivated efforts to design potent inhibitors. Several research groups have synthesized a variety of nucleoside phosphorylase inhibitors that are at various stages of preclinical and clinical evaluation.
mechanism is involved in catalysis by pyrimidine nucleoside phosphorylase (PyNP) :
Pyrimidine nucleosidejphosphate ribose 1-phosphate jpyrimidine base
Studies characterizing the general properties and purification methods of PyNP from horse liver appeared in 1954 [10, 11] , and showed that thymidine was cleaved but that uridine was not. This observation suggested the presence of two PyNPs : one specific for thymidine and one specific for uridine. This was supported by the earlier work of Paege and Schlenk [12] , in which bacterial PyNP was shown to cleave uridine but not thymidine. This work also provided conclusive evidence for a reversible phosphorolytic mechanism for PyNP, analogous to the mechanism determined earlier for PNP. In addition to phosphorolysis, other reactions for cleaving glycosidic bonds have now been identified. The C-N glycosidic bond is hydrolysed in nucleosides and dinucleotides by nucleoside hydrolases, which include examples such as inosinase (EC 3.2.2.2) [13] , uridine nucleosidase (EC 3.2.2.3) [14] , 5h-methylthioadenosine\S-adenosylhomocysteine (MTA\SAH) nucleosidase (EC 3.2.2.9) [15] , AMP nucleosidase (EC 3.2.2.4) [16] and NAD + nucleosidase (EC 3.2.2.5) [17] . The glycoside hydrolase enzymes, which also have a hydrolytic mechanism, cleave the glycosidic linkage in a variety of glycosides, and include examples such as lysozyme (EC 3.2.1.17) [18] , β-galactosidase (EC 3.2.1.23) [19] and neuraminidase (EC 3.2.1.18) [20] . Nucleoside deoxyribosyltransferases catalyse the transfer of purine or pyrimidine bases between nucleosides (e.g. EC 2.4.2.5 and EC 2.4.2.6) and utilize specific residues of the enzyme as the nucleophile in cleaving the glycosidic bond [21] . However, in the absence of a second acceptor base, 2h-deoxyribosyltransferase also shows a secondary hydrolytic mechanism [22] . The phosphoribosyltransferases utilize pyrophosphate in glycosidic bond cleavage, and include examples such as adenine phosphoribosyltransferase (EC 2.4.2.7) [23] , hypoxanthine-guanine phosphoribosyltransferase (EC 2.4.2.8) [24] , nicotinamide phosphoribosyltransferase (EC 2.4.2.11) [25] and anthranilate phosphoribosyltransferase (AnPRT ; EC 2.4.2.18) [26] .
The biochemical significance of glycosidic bond cleavage in purines and pyrimidines by the phosphorolytic mechanism catalysed by PNPs and PyNPs is most apparent in the salvage pathway [27, 28] . The biosynthesis of purine and pyrimidine nucleotides, which are critical compounds in nearly all biochemical processes, can proceed through one of two pathways in the cell : (1) the de no o pathway, which uses a variety of amino acids and other low-level precursors to produce nucleotides, and (2) the salvage pathway, which makes use of preformed nucleobases and nucleosides as precursors in the production of nucleotides. The salvage pathway thus allows the cell to circumvent the energy-costly de no o pathway when appropriate precursors are available. In addition, the side products released in the salvage pathway provide a source of carbon, nitrogen and energy (via the conversion of the ribose moiety into intermediates that can enter the pentose phosphate pathway and glycolysis) to the cell. In addition to its role in the salvage pathway, thymidine phosphorylase (TP) has also been shown to have deoxyribosyltransferase activity, which results in the deoxyribosyl moiety being transferred from one base to another. This transferase activity is also known to play an important role in the metabolism of nucleosides [29] .
Biomedical interest in the nucleoside phosphorylases arises from their key role in nucleotide metabolism and their requirement for normal cellular function. Nucleoside phosphorylases affect the cellular levels of free bases and nucleosides by catalysing their interconversion. It has been suggested that inhibitors of specific nucleoside phosphorylases might potentiate the action of certain nucleoside analogues of chemotherapeutic value by preventing their cleavage and subsequent inactivation [30] . PNP is required for normal T-cell development. Patients lacking PNP have severe T-cell immune deficiency, while B-cell function is unaffected [31] . This clinical profile suggests that inhibitors of human PNP (hPNP) might be used to selectively kill T-cells in T-cell leukaemias and T-cell lymphomas, to suppress the T-cell response after organ transplantation, or to treat T-cellmediated autoimmune diseases [32] . Mammalian TP is associated with angiogenesis. Originally identified as platelet-derived endothelial cell growth factor [33] , TP is now the target of a number of groups seeking to develop inhibitors for the treatment of metastatic tumours.
PNP from Escherichia coli is also of biomedical interest because of the potential to develop cancer treatments that utilize gene therapy to activate nucleoside analogues to their cytotoxic form [34] . In particular, tumour cells transfected with the E. coli PNP gene are able to cleave non-toxic prodrugs such as 6-methylpurine-2h-deoxyribose to the highly cytotoxic base 6-methylpurine [35] . Furthermore, the liberated 6-methylpurine can pass through the cell membrane and kill nearby cells through a ' bystander ' effect. The prodrug is not cleaved by hPNP because of significant differences in substrate specificity between the bacterial and mammalian enzymes. Finally, the nucleoside phosphorylases of some micro-organisms are potential therapeutic targets. Because of the differences in substrate specificity between hPNP and PNPs from micro-organisms [36] , it may be possible to selectively inhibit purine salvage. This might be particularly advantageous in parasitic organisms that lack de no o synthesis and rely entirely on the salvage pathway as a source of purines.
Because of the recent emphasis on functional genomics, and because structure is more highly conserved than sequence, it is becoming ever more important to relate protein structure to protein function. Over the last few years we have shown, using structural studies, that all of the enzymes that catalyse the phosphorolytic cleavage of the glycosidic bond in nucleosides have one of two distinct protein folds. This is the case even though these enzymes show a wide range of substrate specificities and physical properties, and in many cases low sequence identity. The discovery of only two possible folds provides the basis for our definition of two distinct families of nucleoside phosphorylases. Here we define the nucleoside phosphorylase-I (NP-I) family as those enzymes that share a common α\β-subunit fold and show either a trimeric or a hexameric quaternary structure. Members of the NP-I family accept a range of purine nucleosides, as well as the pyrimidine nucleoside uridine. Furthermore, we define the nucleoside phosphorylase-II (NP-II) family to be those enzymes that display a dimeric quaternary structure where each characteristic subunit consists of a small α-domain separated by a large cleft from a larger α\β-domain. Members of the NP-II family accept both thymidine and uridine in lower organisms, but are specific for thymidine in higher species, including humans. The discovery of two distinct protein folds that catalyse the same fundamental biochemical reaction provides a unique example of how Nature makes use of structural diversity to accomplish a common task. and studied from a variety of species. Kalckar [37] was among the first to successfully isolate PNP when he purified the enzyme from rat liver tissue. Later, Kim and co-workers [38] successfully purified and partially characterized PNP from human erythrocytes. PNP has now been isolated and studied from a wide variety of both mammalian (e.g. bovine brain [39] , rabbit liver [40] , calf spleen [41] and hamster [42] ) and bacterial (e.g. E. coli and Salmonella typhimurium [43] , Sulfolobus solfataricus [44] , Erwinia caroto ora [45] and Bacillus cereus T [46] ) species. These studies have revealed two forms of PNP : (1) trimeric PNP, which has a subunit molecular mass of approx. 31 kDa and is specific for guanine and hypoxanthine (2h-deoxy)ribonucleosides ; and (2) hexameric PNP, which has a subunit molecular mass of approx. 26 kDa and accepts adenine as well as guanine and hypoxanthine (2h-deoxy)ribonucleosides. Mammalian species generally possess only the trimeric form of PNP. Bacterial species have largely been shown to possess only the hexameric form, although both a trimeric and a hexameric form have been found in E. coli [47] , Bacillus subtilis [48] and Bacillus stearothermophilus [49] .
Other members of the NP-I family include uridine phosphorylase (UP ; EC 2.4.2.3) and 5h-deoxy-5h-methylthioadenosine phosphorylase (MTAP ; EC 2.4.2.28). UP, which is specific for uridine nucleosides, but also accepts 2h-deoxypyrimidine nucleosides in higher organisms [50] , has been isolated and characterized from a variety of species [51] [52] [53] [54] . Bacterial UP functions as a hexamer with identical subunits that have a molecular mass most commonly reported as 27.5 kDa. A study of UP from a variety of organisms by Krenitsky and co-workers [50] showed two distinct types of UP, as distinguished by pH optima at either 6.5-6.7 or 7.9-8.1. MTAP, which is specific for the purine nucleoside analogue 5h-deoxy-5h-methylthioadenosine, has been isolated and characterized from bacterial and mammalian species [44, 55, 56] . MTAP is reported to function as a trimer in all species with the exception of Sulfolobus solfataricus [44] , in which it reportedly functions as a hexamer. MTAP consists of identical subunits each with a molecular mass of approx. 30 kDa, except in the archaeal enzyme, which has a slightly smaller subunit.
Although nucleoside synthesis is favoured thermodynamically, phosphorolysis generally occurs in i o due to the uptake of the free bases as reactants in subsequent reactions [30, 57] . Several different mechanisms for the phosphorolysis reaction have been suggested for members of the NP-I family from different species. Early kinetic data from human erythrocyte and bovine spleen PNPs indicated that catalysis occurs through a ternary complex of enzyme, phosphate and nucleoside, and that the reaction is sequential rather than Ping Pong [58, 59] . Studies with PNP from bovine thyroid indicated an ordered Bi Bi mechanism, with phosphate binding before the nucleoside [60] , while the reverse order has been reported for the enzyme from bovine brain [39] . A Theorell-Chance mechanism has also been reported for PNP in human erythrocytes [61] . A more recent study reported kinetic data from bovine spleen PNP that are consistent with an orderedsequential mechanism in the phosphorolytic direction, with phosphate binding before the nucleoside, and a random-sequential mechanism in the synthetic direction [62] . Studies based on site-directed mutagenesis, X-ray structures and kinetic data have provided a detailed model for the proposed transition state of PNP [63] [64] [65] . Further studies of the structural mechanisms of Cellulomonas and bovine PNPs suggested a primary role for water in stabilizing the transition state [66, 67] . Kinetic studies of UP from different species have reported both a random-sequential mechanism [52] and an ordered-sequential mechanism in which phosphate is the first substrate to bind and uracil is the first product to leave [68] . Kinetic studies on MTAP have similarly reported both a random-sequential mechanism [69] and an ordered-sequential mechanism in which 5h-deoxy-5h-methylthioadenosine is the first substrate to bind and 5h-methylthioribose 1-phosphate is the first product to leave [70, 71] .
NP-I STRUCTURES
X-ray crystallographic studies in our laboratory and others have now provided several crystal structures of members of the NP-I family in both native and complex forms. The PNP fold was first revealed in studies on the crystal structure of trimeric human erythrocyte PNP (hPNP) in which the native enzyme, as well as complexes with the substrate analogues 8-iodoguanine and 5h-iodoformycin B, were solved at 3.2 A H resolution [72] . The complex with guanine was also reported [32] , and the refinement of the native enzyme was extended to 2.75 A H [73] , the limit of diffraction of the crystals. The structure of PNP from calf spleen (bovine PNP ; bPNP) was first reported at 2.9 A H [74] , and has more recently been reported at higher resolution ($ 2 A H ) in both native and complex forms [75, 76] . Most recently, structures of bPNP have been reported for complexes with acycloguanine [77] and with immucillin, a transition-state analogue [66] . Other trimeric PNP structures include those of Cellulomonas sp. PNP [67] and PNP from Mycobacterium tuberculosis [78] . The first structure of human MTAP (hMTAP) was solved at 1. [84] . This enzyme is similar to E. coli PNP and also catalyses the phosphorolysis of inosine, guanosine and adenosine ; however, E. coli PNP is unable to cleave methylthioadenosine.
Despite species-dependent differences in the quaternary structures of members of the NP-I family (Figure 1a) , the subunit fold is highly conserved. Topology diagrams that are representative of the subunit folds from both the trimeric and hexameric assemblies are shown in Figure 1(b) . The main feature of the common subunit fold of NP-I enzymes consists of a central β-sheet that forms a distorted β-barrel, surrounded by several α-helices (Figure 1c ). hMTAP shows a trimeric quaternary structure very similar to that seen in mammalian PNP, while the structure of E. coli UP reveals a hexameric quaternary structure that is very similar to that of E. coli PNP. The active site in members of the NP-I family consists of adjacent phosphate-and nucleoside-binding pockets. These binding sites are formed by residues from the central β-sheet and the interconnecting loops, and residues from an adjacent subunit. Superimposing representative structures of NP-I reveals that four of the α-helices (H3, H4, H6 and H7, using bPNP numbering as a reference), as well as 12 of the β-strands (A1-A8, 1B, 2B, 3B and 5B), are structurally conserved (Figure 2 ). Other structurally conserved regions include H5 and 4B among bPNP, hPNP and hMTAP, and H1 and H2 among bPNP and hPNP.
It is significant that, with the exception of strand 4B, all of the β-strands are structurally conserved among the structures of the NP-I family. This central β-sheet structural motif, where the nucleoside and phosphate bind at the C-terminal end of the strands, is completely conserved, despite divergence in the sequences among the structures (see below). This suggests a structural motif that is important in binding nucleosides and phosphate and in catalysing the phosphorolysis reaction. Members of the GTPase family bind nucleotides and also incorporate a central β-sheet topology that is similar to that seen in the C-terminal half of structures of the NP-I family. The conserved helices are also likely to play an important role in the structure-function relationship of the NP-I family. The four conserved helices are distributed on both sides of the central β-sheet and contribute to the overall stability of the α\β-fold. In addition, the N-terminal region of H6 contributes active-site residues to the phosphate-binding site. The most highly conserved region in the structures of NP-I members is the region including the loop between β-strands 5A and 1B, and between 1B and 6A. This loop region connects β-sheets A and B and contributes a residue (Ala-116 in bPNP) to the phosphate-binding pocket.
NP-I SEQUENCE COMPARISONS
The sequences of all known members of the NP-I family have been gathered from the protein databases using standard search- ing methods, and have not revealed any significant relationships with other protein families. Sequence comparisons of the known structures of NP-I enzymes alone suggest two NP-I subfamilies. There appears to be obvious identity among sequences with a known trimeric quaternary structure, and also among sequences with a known hexameric quaternary structure (Table 1) . However, little sequence similarity is seen between the trimeric and hexameric NP-I subfamilies. Despite the lack of similarity between the trimeric and hexameric sequences, the structural similarity between the hexameric and trimeric monomers suggests a common ancestor. This subdivision in the NP-I family is also seen using the BLAST algorithm [85] to search the protein databases, where NP-I sequences fall into one of two groups : one subfamily shows greater similarity to the trimeric PNPs, while the other subfamily shows greater similarity to the hexameric PNPs. A sequence grouped in one NP-I subfamily does not detect a member of the other subfamily using standard searching methods. This sequence analysis has revealed that the trimeric subfamily can be divided further into PNP and MTAP sequences, while the hexameric subfamily can be divided further into PNPs, UPs and a set of uncharacterized hypothetical proteins. Multiple sequence alignments of each of these subfamilies are shown in Figure 3 . A motif analysis of all known sequences of the NP-I family has revealed interesting results that help to clarify what distinguishes a trimeric from a hexameric sequence [86] . Highly conserved regions of the sequences were determined using the MEME software [87] , and examined with regard to their structural location. The analysis identified nine structural regions within the NP-I fold ( Figure 4 and Table 2 below) where motifs were found. The structural regions are labelled A-I. The motifs for specific groups of enzymes are labelled A j -I j , where the subscript j indicates the group number for motifs that have different sequences but occur in the same structural region. The sequences that contain these motifs and their location in the primary sequence have been indicated in the multiple sequence alignments in Figure 3 . The subfamily sequence specificity of each motif has also been indicated in Figure 4 . Of the nine corresponding structural regions where the NP-I sequences are highly conserved, seven are involved in the active site, and six are involved in intersubunit contacts. With the exception of motif A "
, which was found in all NP-I sequences, all of the motifs discovered were specific to either the trimeric or the hexameric subfamilies. The A " motif is important, since it is the only motif that is found in sequences from both the trimeric and hexameric subfamilies. The A " motif makes up the C-terminal end of β-strand 5A in bPNP, β-strand 1B, followed by a β-turn and the N-terminal portion of β-strand 6A. Comparing the structures of the NP-I family shows that there is a high degree of structural similarity in this region (see Figure 2 ). The structural conservation of this region is likely to be due to its proximity to and, consequently, its function in the active site. The beginning of this motif forms a portion of the phosphate-binding site (Ala-116 in bPNP), while the subsequent C-terminal portion of strand 1B and the subsequent loop, although not providing residues having direct contact with the purine base, nevertheless form the backside surface of the base-binding site. Mushegian and Koonin [88] found a similar motif in residues 111-134 of hPNP and in residues 85-108 of E. coli PNP. Sequence motifs that occur in corresponding structural regions where inter-subunit contacts are formed and appear to specify the trimeric quaternary structure include C " , E " and G " , while those that specify the hexameric quaternary structure include B
It is likely that the highly conserved motifs in these regions are important in maintaining either the trimeric or the hexameric quaternary structure of the NP-I fold, and represent regions that differentiate members of the trimeric subfamily from members of the hexameric subfamily.
Several of the motifs occur in the active site of the NP-I fold. Active-site motifs that are only found in trimeric sequences include B "
and H " , while motifs in the active site of hexameric sequences include B # , C # , D # and E # . It has been noted previously from structural comparisons of trimeric and hexameric PNPs that different modes of both phosphate and nucleoside binding exist [80] . Four motif regions involved in phosphate binding show specific motifs for the trimeric PNP sequences (B " , D " , E " and F " ) and for the hexameric PNP sequences (B # , D # and E # ). A motif similar to B # has been reported previously [88] within residues 171-204 of E. coli PNP, although no structural or functional significance was noted. The E region is particularly interesting, since it contains residues that form a catalytic triad thought to be important in phosphate binding in bPNP, but which is not present in E. coli PNP. Mushegian and Koonin [88] speculated that a large motif in E. coli PNP (residues 48-77) is involved in phosphate binding. This motif corresponds to motifs E # and F # in our analysis. Similar to the motif regions that are involved in phosphate binding, there are two regions that are involved in nucleoside base binding that show specific motifs in the trimeric sequences (C " and H " ) and in the hexameric sequences (C # and H $ ). These motifs are likely to play an important role in the differences in purine nucleoside specificity that exist between trimeric and hexameric forms of the NP-I family.
Two motifs (E $ and H # ) have been found only in MTAP sequences, and may be distinguishing factors for MTAP function. It is significant that the loop region where E $ occurs forms part of the binding site that is near the 5h position of the ribose moiety wherein lies the specificity of the MTAP substrates. A unique sequence in this region may be important for the specificity of MTAP and would contribute to distinguishing it from PNP. Motif H occurs in β-strand 8A and part of the preceding loop, and contributes the active-site residue Asn-243 in bPNP. This residue is required both for catalysis and for conferring specificity for 6-oxo purine substrates. It is interesting that, in the case of MTAP, which binds the adenosine base and is thus specific for the 6-amino position, there is a unique sequence located in the functional region of this specificity. Due to the difference in substrate specificity between PNP and MTAP, it is perhaps not surprising that there are distinct motifs in the MTAP sequences that differentiate them from the general trimeric sequences of the NP-I family.
NP-I ACTIVE-SITE ANALYSIS
A structural comparison of the NP-I active sites provides a meaningful perspective concerning the relationships that exist in members of this family. While the phosphorolysis reaction is common to all enzymes of the NP-I family, there are significant differences in nucleoside specificities among the family members. Trimeric PNPs (e.g. bPNP and hPNP) are specific for 6-oxo Two distinct families of nucleoside phosphorylases purine nucleosides, whereas the hexameric PNPs accept adenosine in addition to 6-oxo purine nucleosides. MTAP is specific for 5h-methylthioadenosine, but will accept various substrate analogues such as 5h-methylselenoadenosine, 5h-ethylthioadenosine and 5h-n-propylthioadenosine [56, 89] . UP accepts only pyrimidine nucleosides and lacks specificity at the 2h-ribose position in higher organisms [50] . However, UP will not cleave cytidine, which is not cleaved by any known nucleoside phosphorylase. Previous work in our laboratory has reported a detailed comparison of the active sites and substrate-binding modes in trimeric and hexameric PNPs [80] , and showed that the trimeric and hexameric subfamilies have significant differences in the positions of active-site residues. Schematic diagrams representing the active sites in each of the subfamilies of NP-I are shown in Figure 5 (below). While the members of the NP-I family all bind P i and a nucleoside, which subsequently undergo a phosphorolysis reaction, the modes of substrate binding show significant variation, and help to explain the differences in substrate specificity.
Binding of the phosphate ion is known to induce conformational changes in the loop regions between strand 1A and helix H2, and between strands 2A and 3A, of the bPNP structure [76] . When structures of trimeric and hexameric forms of PNP are superimposed, both the phosphate-and nucleoside-binding sites also superimpose, although the orientation of the phosphate with respect to the nucleoside in the hexameric PNPs is slightly different than in the trimeric forms. The phosphate-binding pocket is located at the C-terminal edge of the central β-sheet (see Figure 1c) . The positioning of the active-site residues of each member of the NP-I family, after superimposing the phosphate ions of each structure, is shown in Figure 6 . There is a significant similarity among the active-site residues of trimeric structures (hMTAP and bPNP), while the hexameric structures (E. coli PNP and UP, whose active site has not been as well characterized) appear to utilize different residues for binding the phosphate ion. In bPNP and hMTAP, several residues are structurally conserved and show the same phosphate-binding interactions. These include Ser-33 in bPNP and Thr-18 in hMTAP ; Ala-116 and Ala-94 ; Ser-220 and Thr-197 ; and Arg-84 and Arg-60. The side chains of His-64 in bPNP and His-61 in hMTAP are also in the same position in binding the phosphate ion, but interestingly come from regions that are not structurally conserved. There is also an interaction in hMTAP between the side chain of Thr-93 and O-3 of the phosphate ion which corresponds to an interaction with a water molecule in bPNP. None of the other structures contain a residue that corresponds to His-86 of bPNP, which, along with Glu-89 and phosphate, form a possible catalytic triad. Of the active-site residues in the hexameric structures, only Ser-90 and Arg-87 of E. coli PNP occur in a region that is structurally conserved among all members 
Table 2 Highly conserved sequence motifs found in the NP-I sequences
The structural location of each motif is indicated by its label with reference to Figure 4 . For each motif, the residue numbers from one representative sequence with known three-dimensional structure are listed for reference. The corresponding structural and functional significance is also listed for each motif. of the NP-I family. It is significant that these two residues occur in the highly conserved β-strand and loop region (motif A " corresponding to strands 1B and 6A, and the interconnecting loop). The rest of the phosphate-binding residues in the hexameric structures (including two arginine residues) come from loop regions that are not structurally conserved, or from a helix that is only conserved among hexameric structures. The nucleoside-binding pocket is also located along the Cterminal edge of the central β-sheet, adjacent to the phosphatebinding site (see Figure 1c) . A large flexible loop region (residues 246-265) in bPNP and hPNP may act as a gate that allows the entrance and exit of substrates and reaction products [32] . Part of this loop region undergoes a significant structural change when nucleoside binds, where the N-terminus of helix H7 is extended to include residues 257-265. The corresponding loop in the hexameric structures is much shorter and does not undergo a similar transition. The positioning of the active-site residues of each member of the NP-I family, after superimposing their nucleoside substrates, is shown in Figure 6 . The residues that interact with the ribose moiety show a significant similarity in the group of methionine residues from all four structures that form a hydrophobic interaction with the ribose ring. The corresponding methionine in bPNP (Met-219) occurs in a loop following β-strand 4B. Although this region is not structurally conserved among trimeric and hexameric structures, the corresponding residues are close enough to effectively position the methionine side chains in the same general location near the ribose ring. This methionine is absolutely conserved in all known sequences of the NP-I family. Another significant similarity involves active-site residues that participate in a hydrophobic pocket near the 5h position of the ribose ring. His-137 from hMTAP, Phe-159 from bPNP and His-4 from E. coli PNP all come from neighbouring subunits of the PNP molecule. His-137 and His-159 are structurally conserved in hMTAP and bPNP (in a large loop between β-strand 2B and helix H4 in bPNP), while His-4 in E. coli PNP comes from a completely different region of the PNP fold. His-257, which is part of the large flexible loop in bPNP, is also near this position, where it binds the 5h-OH of the ribose ring and subsequently participates in the conformational change in residues 257-265 discussed above. It is significant that no other residues in the other structures correspond to His-257. Val-233 of hMTAP is in roughly the same position, but is involved in a hydrophobic pocket that probably contributes to the binding of the 5h-deoxy-5h-methylthio group of MTAP substrates. Significant similarities in residues that are involved in base binding include the herringbone stacking interaction that involves Phe-200 of bPNP, Phe-177 of hMTAP, Phe-159 of E. coli PNP and Phe-162 of E. coli UP. Of these residues, only those from bPNP and hMTAP are structurally conserved (in a loop between β-strand 3B and helix H5 in bPNP), although the side chains in both trimeric and hexameric structures are positioned to be perpendicular to the plane of the purine or pyrimidine base. The interaction between Glu-201 of bPNP and N-1 of the purine base corresponds to an interaction with a water molecule in hMTAP ; no residues from the hexameric structures form interactions at this position. The majority of the base specificity is likely to occur at the 6-position, where residues of all four structures are in structurally conserved positions in β-strand 5B. The aspartic acid side chains in hMTAP and E. coli PNP (Asp-220 and Asp-204 respectively) allow for hydrogen bonding with the 6-amino purine nucleosides, while Asn-243 of bPNP specifies 6-oxo purine nucleosides. Val-221 in this position in E. coli UP is probably contributing to a hydrophobic pocket thought to be near the 5-position of the pyrimidine ring. Asp-222 of hMTAP is also in a position to hydrogen-bond with the 6-amino position of the MTAP substrates.
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Figure 5 Schematic drawings of a representative active site of each NP-I subfamily
A study based on structural and kinetic analyses of a trimeric PNP has suggested a possible catalytic mechanism for hPNP [64] that is likely to be similar in all members of the NP-I family. Several bPNP-substrate-analogue complexes have been solved in our laboratory, and these suggest that the β-nucleoside binds in a high-energy janticlinal torsion angle of the glycosidic bond, with the ribose moiety in the uncommon C-4h-endo sugar pucker [76] . The proposed mechanism for hPNP suggests that this highenergy conformation produces steric strain, which encourages glycosidic cleavage. The glycosidic bond is weakened further as electrons flow from O-4h of the ribose to the purine ring, and this results in an oxocarbenium ion that is stabilized by the negative charges of the phosphate ion. The phosphate ion binds on the α-side of the ribose ring, where it is positioned to participate in an S N 1 nucleophilic attack at the C-1h position. The flow of electrons from the glycosidic bond to the purine ring is probably stabilized
Figure 7 Proposed catalytic mechanism for hPNP, representative of a likely mechanism for all NP-I family enzymes
by active-site-residue interactions at the N-7 position. A recent structural study by Fedorov et al. [66] provided additional details of the atomic motions that are responsible for catalysis. The analogous flow of electrons to the pyrimidine ring in E. coli UP is likely to be stabilized by hydrogen-bond-donor interactions with the O-2 and O-4 positions. A schematic diagram of the proposed catalytic mechanism in hPNP is shown in Figure 7 , and is representative of a likely mechanism for all members of the NP-I family.
NP-I EVOLUTIONARY ASPECTS
Protein structure is often conserved among distant members of a protein family, although the nucleotide sequences have diverged beyond recognition. Structural information, when available, can thus serve as a much more sensitive probe in determining ancient relationships than sequence identity alone. The NP-I family shows a conserved subunit fold, even though there is a quaternary structural division between trimeric and hexameric forms. Although the sequence identity between members of the trimeric and hexameric subfamilies is below the level normally used to establish an evolutionary relationship, the structural similarity confirms their relationship. Based on the division between the trimeric and hexameric subfamilies with regard to their overall sequence, as well as in sequence motifs, a phylogenetic scheme is suggested as shown in Figure 8 . A likely early evolutionary event was the divergence of an ancient NP-I fold into trimeric and hexameric family members. The trimeric structure continued to diverge and specialize, resulting in the PNPs that are now commonly found in eukaryotes as well as some prokaryotes, and the MTAP structure that is found in a variety of organisms. The hexameric family may also have diverged, resulting in the hexameric PNP structure found only in prokaryotic cells and the hexameric UP structure that is found in a variety of organisms. In addition, the hexameric subfamily of NP-I may also have diverged into a third category of as yet uncharacterized hypothetical proteins. The evolutionary pathway in Figure 8 suggests divergent evolution from a common ancestor that perhaps accepted a wide range of nucleoside and\or nucleotide substrates and then became more specialized for particular nucleosides over time. It is also possible, however, that the NP-I family resulted from convergent evolution, whereby the enzymes that we know today have evolved from several disparate sources. In this case, the common folds of the NP-I family would have been formed independently, as a result of the need to catalyse similar reactions with similar substrates.
Iterative BLAST searches starting with various members of the NP-I family reveal similarities between the monomer fold and both MTA\SAH nucleosidase and AMP nucleosidase. The similarity is greatest between the nucleosidases and the hexameric NP-I family members. Like nucleoside phosphorylases, nucleosidases cleave the glycosidic bond ; however, unlike nucleoside phosphorylases, nucleosidases utilize water as the nucleophile. Further examination of the nucleosidase sequences revealed that several key residues in the nucleoside-binding site were conserved. However, all three arginine residues, which account for most of the phosphate-binding site in the nucleoside phosphorylases, have been replaced by neutral amino acids. The similarity to the NP-I family has now been confirmed by the crystal structure of MTA\SAH nucleosidase from E. coli [90] . The structure shows that the fold is indeed conserved but, in contrast with the other NP-I members, MTA\SAH nucleosidase is dimeric. The structure of AMP nucleosidase has not yet been determined.
PNP INHIBITOR DESIGN
Inhibitors of PNP have the potential to help prevent the degradation and deactivation of nucleoside analogues used in chemotherapeutic treatments [91, 92] . PNP deficiency has additionally been linked to several immunological diseases, such as T-cell immune deficiency [31, 93, 94] . Inhibitors of PNP have the potential to suppress the T-cell response in T-cell proliferative diseases such as T-cell lymphoma and T-cell leukaemia, as well as in T-cell-related autoimmune diseases such as rheumatoid arthritis and lupus. This method of suppressing T-cells may also find application in organ transplantation, where the donated organ is often rejected due to a massive T-cell response. Despite the potential benefits of a potent inhibitor of PNP activity, thus far no drug has reached the clinic.
Effective in i o inhibitors have been difficult to obtain, presumably due to the high levels of PNP in humans, particularly in lymphoid tissues and in erythrocytes, which necessitates a very potent binding affinity. One of the first known inhibitors of PNP was the guanine analogue 8-aminoguanine, which showed a K i of 0.2 µM [30] with human erythrocyte PNP. Prompted by its structural similarity to the natural substrates of PNP, the antiherpetic agent acyclovir and its metabolites, which belong to the class of nucleoside analogues known as acyclic nucleosides, were also tested for PNP inhibition and shown to have significant binding properties. Tuttle and Krenitsky [95] showed that the phosphorylated metabolites of acyclovir, using a physiological phosphate concentration of 1 mM, had K i values of 6.6, 0.0087 and 0.31 µM for the mono-, di-and tri-phosphate esters respectively. A later study [96] of acyclovir phosphate metabolites further investigated their binding properties with PNP, and showed that the inter-atomic distance between the carbon of the 9-substituent of the guanine and the terminal oxygen anion is a critical factor in determining binding affinity for hPNP. That study showed the diphosphate to be of optimal length, explaining why it binds better than the mono-or tri-phosphate acyclovir esters. Despite the favourable binding properties of acyclovir diphosphate, its inability to permeate membranes and its susceptibility to metabolism limit its potential as a clinically useful drug. Other nucleoside analogues that have been tested for inhibition of PNP include a series of 9-phosphonoalkylhypoxanthines, of which the most effective showed a K i of only 0.9 µM [97] . In addition, many ring analogues of guanine and hypoxanthine and the corresponding nucleosides have been tested for PNP inhibition, but, with the exception of the 9-deazapurines, none are as effective as the 8-aminoguanine compounds discussed above [98] .
The first attempts to rationally design PNP inhibitors based on the three-dimensional structure of the enzyme were reported by Ealick and co-workers [32] . The crystal structures of PNP in complex with several known potent nucleoside analogue inhibitors revealed important hydrogen-bonding patterns in the base-binding site involving residues Glu-201, Thr-242 and Asn-243, and showed the interactions in the ribose-binding site to be largely hydrophobic. Structures of complexes also showed how the 8-amino group enhanced binding in guanine analogues, but had the opposite effect in 9-deazaguanines. This study [32] also verified that the acyclovir diphosphate was indeed a multisubstrate inhibitor, occupying the base-and phosphate-binding sites. The crystal structure of hPNP in complex with acyclovir diphosphate showed the spacer length between N-9 and the phosphate ion to be optimal for occupying both the baseand phosphate-binding sites. These structural studies suggested that optimal inhibitors of PNP would take advantage of the base-, ribose-and phosphate-binding sites. This prompted further rational design efforts using iterative cycles of modelling of potential inhibitors into the active site of the hPNP structure, synthesis of potentially high-affinity compounds, and testing of the compounds using X-ray structure determination and measurement of specific binding affinities. These efforts resulted in a series of 9-substituted 9-deazapurine analogues with various aromatic, heteroaromatic and cyclic aliphatic substituents that would occupy the hydrophobic ribose-binding site, followed by a substituent that would have affinity for the phosphate-binding site. The first set of studies focused on a series of 9-(arylmethyl) derivatives of 9-deazaguanine, which showed IC &! values that ranged from 17 to 120 nM ; 9-(3,4-dichlorobenzyl)-9-deazaguanine was the most potent of this series [99] . Further studies demonstratedd a series of 9-alicyclic and 9-heteroalicyclic derivatives of 9-deazaguanine to have similar IC &! values ; 9-(2-tetrahydrothienylmethyl)-9-deazaguanine showed the highest affinity for hPNP, with an IC &! of 11 nM [100] . Continued studies resulted in a series of 9-(arylmethyl)-9-deazaguanine analogues that were substituted at the methylene group. This resulted in the highest-affinity compound of this work : the membrane-permeant PNP inhibitor (S )-9-[1-(3-chlorophenyl)-2-carboxyethyl]-9-deazaguanine, which had an IC &! of 5.9 nM in an in itro assay [101,101a] . The results of these studies suggested that the optimum spacer between the hydrophobic and the phosphate-binding regions is 2-4 carbon atoms, and that between the purine ring and the hydrophobic substituent is a single methylene group. It was also shown that acyclic hydrophobic substituents at the 9-position alone were poor inhibitors, which suggested that a rigid structure is necessary in the hydrophobic ribose-binding pocket.
The favourable characteristics of the binding of acyclovir diphosphate to hPNP, in addition to its lack of stability in i o, have prompted additional X-ray structural studies based on analogues of acyclovir diphosphate [102] . The study tested various phosphate mimics, including sulphonic acid and carboxylic acid groups, which interact favourably with the phosphate-binding site in hPNP. This resulted in the synthesis of 9-(3,3-dimethyl-5-phosphonopentyl)guanine, which has an IC &! of 44 nM. Kelley and co-workers [103] synthesized and tested a series of o[(guaninylalkyl)phosphinoco]methylqphosphonic acids in an effort to produce an acyclovir diphosphate analogue that was stable in i o while retaining high affinity for hPNP. The most potent compound of this series was (o[5-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)pentyl]phosphinocoqmethyl)-phosphonic acid, which showed a K i of 3.1 nM and required Zn# + ions for optimal activity, but showed only weak activity against human leukaemic T-cells in itro. A recent study, which focused on designing transition-state analogues of PNP, has produced the most potent inhibitors thus far [104] . These inhibitors incorporate features of the transition state, including an elevated pK a at N-7 of the purine ring and a positive charge in the ribose ring that mimics the formation of an oxocarbenium. The most potent compounds are (1S )-1-(9-dezahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino--ribitol (immucillin-H) and (1S )-1-(9-deazaguanin-9-yl)-1,4-dideoxy-1,4-imino--ribitol (immucillin-G), which showed K i values that ranged from 23 to 72 pM when tested against calf spleen and human erythrocytic PNP. Further studies are required to determine if such compounds will be successful in the clinic.
NP-II FAMILY
Following the discovery of a distinct enzyme for the phosphorolysis of pyrimidines, several studies characterized PyNP further. Several works confirmed the suggestion by Paege and Schlenck [12] that there existed two separate PyNPs. Laster and Blair [105] , for example, reported that a UP from mammalian tissue did not distinguish between the ribose moieties of uridine and thymidine, while a distinct TP was specific for the 2h-deoxyribose moiety of thymidine. The work of Krenitsky and coworkers [50] solidified this hypothesis and established a general definition of the two major classes of PyNPs : TP and UP. This study, which included PyNPs from a broad range of bacterial and mammalian species, again confirmed the presence of two distinct pyrimidine-cleaving enzymes. Nevertheless, it was shown that the specificity for the ribose moiety, as well as the specificity at the 5-position of the pyrimidine ring, varied among species. TP was also reported to be distinct in its pH optima, as the TP class had a general pH optimum of 5.5.
The deoxyribosyltransferase activity was attributed to TP in the works of Zimmerman and Seidenberg [106, 107] . Later studies verified this activity, and also showed that deoxyribose 1-phosphate and the pyrimidine base bind at two distinct locations in the enzyme [108] . It was further shown [109] that the deoxyribose 1-phosphate is a free intermediate, so that the Two distinct families of nucleoside phosphorylases transferase activity, involving two pyrimidine bases B1 and B2, is likely to take place via a two-step mechanism as follows (where dR is deoxyribose and dR-1-P is deoxyribose 1-phosphate) :
B1-dRjP i B1jdR-1-P dR-1-PjB2 B2-dRjP i TP and UP have now been isolated and characterized from a wide variety of species. In all cases, TP functions as a dimer, ranging in molecular mass from 80 kDa in Lactobacillus casei [110] to 110 kDa in human blood platelets [111] , while UP functions as a hexamer, with a reported molecular mass of 165 kDa in E. coli [112] . Structural analysis indicates that E. coli UP belongs to the NP-I family, as discussed above. These studies suggest that the discriminating feature between UP and TP is the high specificity of TP for the 2h-deoxyribose moiety. TPs from rat liver [113] , mouse liver [51] , horse liver [10] , E. coli [114] , and Lactobacillus casei [110] have shown such specificity for the 2h-deoxyribose moiety. In all cases, the 5-position of the pyrimidine ring was less important in determining specificity than was the 2h-position of the ribose moiety. Several organisms, such as Bacillus stearothermophilus [115] and Haemophilus influenzae [116] , however, are reported to contain a single PyNP that does not discriminate at the 2h-position of the ribose. Enzymes that accept both thymidine and uridine as substrates are referred to as PyNPs. PyNPs and TPs show significant sequence similarity and have similar physical properties. Our X-ray crystallographic studies showed that the three-dimensional structures of Bacillus stearothermophilus PyNP [117] and E. coli TP [118, 119] are also similar.
Kinetic studies of TP from several species generally agree on a sequential mechanism. Studies of TP from E. coli [109] and rabbit muscle [120] suggest an ordered sequential mechanism, with phosphate binding before thymidine, and thymine being released before deoxyribose 1-phosphate. These results are corroborated by evidence that phosphate or deoxyribose 1-phosphate stabilizes the enzyme, but thymidine or thymine does not [121] . TP from Lactobacillus casei [110] shows a sequential mechanism with a random order of addition but an ordered release of products, where the release order is the same as that seen in E. coli and rabbit muscle enzymes. Mouse liver TP is reported to have a sequential mechanism with random order for both addition and release [122] .
The expression of TP, like that of PNP and other nucleosidebinding enzymes, is inducible by the addition of deoxyribonucleosides. This induction suggests that these enzymes may share common regulatory factors. Further evidence suggests that this induction effect is due to the formation of deoxyribose 5-phosphate [123] . More recently, TP activity has also been reported to be inducible by interferon and other cytokines in several cancer cell lines [124, 125] . Recently, increased interest in TP has focused on several intriguing findings. Platelet-derived endothelial cell growth factor, characterized by its angiogenic and endothelial cell chemotactic activities, was shown to be identical with human TP [126] . Similarly, gliostatin, characterized by its inhibition of glial cell growth and subsequent stimulation of neuronal survival, was also shown to be identical to human TP [127] . The relationship between these growth-factor activities and the phosphorylase activity is as yet unknown. TP is expressed in a wide variety of human tissues, with levels of expression varying up to 15-fold in different tissues. It is significant that TP levels in carcinomas of the stomach, breast, colon and ovary are elevated up to 10-fold in comparison with those in the corresponding nonneoplastic tissue [128] [129] [130] [131] [132] . This increase in activity in malignant tissue is likely to be associated with the growth-factor activity of TP. In view of these recent findings, understanding the structurefunction relationship of TP has become an even more important focus.
NP-II STRUCTURES
Detailed structural information on the NP-II family was initially provided by the 2.8 A H crystal structure of E. coli TP [119] . The three-dimensional structure of TP reveals an S-shaped homodimer in which each subunit contains a large mixed α-helical and β-sheet domain (the α\β-domain) which is separated from a smaller α-helical domain (the α-domain) by a large cleft ( Figure  9 ). Three loop regions connect these two domains. This fold represents a unique α\β-fold that is unrelated to the fold observed in the NP-I family. The topology of the NP-II fold is shown in Figure 10 . The active site of each subunit consists of a thymidinebinding site in the α-domain and a phosphate-binding site across the cleft in the α\β-domain. The large distance between the phosphate-and thymidine-binding sites (8 A H ) reported in E. coli TP suggested that rigid-body domain movement, where the loop regions connecting the two domains act as hinge regions, may be necessary to close the cleft and enable catalysis to proceed. The structure solution of E. coli TP in three different crystal forms provided evidence for a domain movement [118] in which the domains move as rigid bodies. The monoclinic crystal form of E. coli TP showed the enzyme in the most open conformation, the orthorhombic form was intermediate, and the tetragonal form, which showed a sulphate ion bound in the phosphate-binding site, was the most closed. Further evidence for domain movement and subsequent cleft closure was obtained when we solved the crystal structure of PyNP from B. stearothermophilus in complex with phosphate and the substrate analogue inhibitor pseudouridine in a completely closed conformation [117] . These structures suggest that binding of phosphate causes an initial 8m rotation of the α\β-domain. Binding of the pyrimidine causes an additional 20m rotation, which produces a closed-cleft active conformation of the enzyme. The different relative orientations of the α-and α\β-domains observed in the TP and PyNP structures are shown in Figure 11 . The crystal structure of PyNP in the closed conformation suggests a functional role for the dimeric structure, whereby side-chain residues from the α\β-domain form interactions across the cleft with residues from the α-domain of the other subunit.
Figure 11 Ribbon drawing of the superposition of a single subunit from the known structures of the NP-II family where the α/β-domains have been aligned
The β-strands of all models are coloured green, and the α-helices are coloured grey. The colouring of the loop regions distinguishes each model as follows : red, B. stearothermophilus PyNP in the closed-cleft conformation ; blue, monoclinic form of E. coli TP ; yellow, orthorhombic form of E. coli TP ; violet, tetragonal form of E. coli TP.
NP-II ACTIVE SITE
The phosphate-binding pocket is located between two β-strands near the C-terminal end of the central β-sheet of the α\β-domain. Residues that bind phosphate come from these two strands as well as from a nearby loop. Phosphate binding causes the loop region comprising residues 115-120 in E. coli TP to become ordered, resulting from the formation of a key hydrogen bond between His-119 and Gly-208. This step is thought to be responsible for the initial 8m rotation of the α\β-domain. The pyrimidine-binding pocket is formed from residues in the two helices on the face of the α-domain facing the cleft. The primary interactions include binding of the two carbonyl groups of the pyrimidine ring by positively charged arginine and lysine residues, as well as a herringbone base-stacking interaction between the pyrimidine base and a tyrosine residue. Binding of the pyrimidine base in the α-domain is thought to interrupt a salt bridge between Lys-187 and Asp-161 in B. stearothermophilus PyNP. This allows the formation of a β-turn in one of the inter-domain connecting loops and is responsible for rotating the α\β-domain an additional 20m into its fully closed position.
The crystal structure of PyNP from B. stearothermophilus has identified active-site residues thought to be involved in binding the substrates, as shown in Figure 12 . The active-site residues shown in Figure 12 are highly conserved among all sequences of the NP-II family (discussed below). The PyNP crystal structure provides an example of a member of the NP-II family that accepts both thymidine and uridine. Comparison of the active Figure 12 Active-site residues in the PyNP structure in a closed-cleft conformation Figure 13 Proposed catalytic mechanism for the NP-II family, analogous to that of the NP-I family sites in the structures of E. coli TP and B. stearothermophilus PyNP suggests one possible explanation for this difference. In both E. coli and human TP, which are reported to be specific for the 2h-deoxyribose moiety, a methionine residue replaces Lys-108 of PyNP. This substitution may create a different hydrogenbonding scheme with the phosphate oxygen that binds to the 2h-hydroxy group of the ribose moiety, and may account for the difference in substrate specificity [117] . The crystal structure of PyNP in a closed conformation also suggests that the pyrimidine nucleoside binds in a high-energy conformation with a glycosidic torsion angle that is classified as jantiperiplanar and an unusual C4h-endo pucker of the sugar ring. A similar high-energy conformation was noted previously in the PNP structures of the NP-I family. The overall orientations of the nucleoside and phosphate ion are also very similar to those observed in the structures of the NP-I family.
Although the catalytic mechanism for the NP-II family has not been studied to the same extent as for PNP, it is likely that the mechanism is very similar in nature to that proposed for hPNP. A proposed mechanism for the NP-II family is shown schematically in Figure 13 . The steps of this mechanism are analogous to those discussed above for the NP-I family, and begin with weakening of the glycosidic bond due to the highenergy conformation of the bound pyrimidine nucleoside. The glycosidic bond is weakened further as electrons flow from O-4h of the ribose moiety (where an oxocarbenium ion is subsequently formed) to the pyrimidine ring, and are stabilized through interactions with the positively charged lysine and arginine residues. The phosphate ion, which binds on the α-side of the ribose ring, is then positioned to attack the C-1h position of the ribose ring to yield α-ribose 1-phosphate and the free pyrimidine base. The role of His-82, which is absolutely conserved in the NP-II family (see Figures 13 and 14) , in the mechanism is not known, but it could potentially be involved in stabilizing the transition state, or donating a proton to the C-1 position of the pyrimidine ring following glycosidic cleavage.
NP-II SEQUENCE ANALYSIS
Members of the NP-II family show a high degree of sequence similarity : all the known sequences share between 33 % and 67 % identity, and thus are expected to have similar structures. The similarity in sequences of enzymes belonging to the NP-II family is shown in Figure 14 . Residues in the α-domain are more highly conserved than residues in the α\β-domain. Use of standard searching methods has revealed a possible relationship with the sequence of AnPRT, which has also been noted in a motif study involving sequences from both PNPs and PyNPs [88] . AnPRT catalyses the second step in tryptophan biosynthesis, in which phosphoribosylanthranilate and pyrophosphate are formed from anthranilate and phosphoribosyl pyrophosphate [26] . AnPRT from Hafnia al ei is reported to function as a homodimer with a molecular mass of 70 kDa [133] . The Nterminal regions of NP-II sequences and AnPRT show the most significant similarity. A motif study in our laboratory [86] has also shown AnPRT sequences to share significant similarities with the phosphate-binding region in NP-II sequences. The similarities between PyNP and AnPRT, including the reactions catalysed, the properties of the reactants and products, the amino acid sequences and the quaternary structures, suggest a possible structural relationship between these two enzymes. AnPRT has been crystallized previously [133] , and a preliminary description of the structure has recently been reported [134] . That study confirmed that AnPRT is homologous with members of the NP-II family, and distinctly different from any other previously reported phosphoribosyltransferase structures [135] [136] [137] [138] [139] [140] [141] [142] .
NP-II INHIBITOR DESIGN
Inhibiting TP is of therapeutic interest for several reasons. Inhibition of the nucleoside salvage pathway may be an effective chemotherapeutic strategy in cancer, since some tumour cells depend heavily on this pathway for their proliferation [143, 144] . In addition, various fluoropyrimidines have been used widely as chemotherapeutic agents ; the catalytic action of TP on the glycosidic bond of these pyrimidine analogues is thought to be a key step in their activation and regulation [145] [146] [147] [148] . Inhibitors may therefore be useful in modulating these reactions in both the synthetic and phosphorolytic directions, as well as with regard to the ribosyltransferase activity. Gene therapy has been suggested as a means of providing tissue-directed expression of TP [149] . It has furthermore been shown that specific thymidine concentrations, administered concurrently with various fluoropyrimidines, can be cytotoxic to several tumour cell lines [150] [151] [152] . Thus being able to control thymidine levels in i o may be useful in various chemotherapeutic strategies. The recent discovery that TP also functions as an angiogenic growth factor and is found in abnormally high levels in several tumour cell lines draws even more attention to this enzyme as a drug target in cancer treatment.
Most inhibitors of TP are pyrimidine or pyrimidine nucleoside analogues. Several early studies reported on the binding properties of 1-substituted uracil rings [153] , 5-and 6-substituted uracil rings [154] , 1-substituted uracil rings with the addition of various hydrophobic substituents at the 5-and 6-positions [155] , and 5h-substituents of thymidine, as well as various other substitutions on the ribose ring [156] . A later study by Baker and Kelley [157] reported on 80 different uracil compounds with hydrophobic substituents at the 1-, 5-or 6-positions. These compounds were tested for binding affinity for TP from both rabbit liver and E. coli. The most effective inhibitors from this study were those containing a 2,4-dimethylanilino, phenethylamino or phenylbutylamino substituent at the 6-position, which had IC &! values that ranged from 53 to 110 µM for TP from rabbit liver. Studies of pyrimidine acyclonucleosides showed acyclothymidine [5-methyl-1-(2h-hydroxyethoxymethyl)uracil] to be an effective inhibitor of UP (K i 3 µM), but it did not inhibit TP [158] . A more recent study, however, suggests that acyclothymidine may be an effective inhibitor of both UP and TP [159] . This suggestion resulted from studying the inhibition of the phosphorolysis of 5h-deoxy-5-fluorouridine in intestinal homogenates from human, rabbit, rat and mouse. Acyclothymidine was shown to be the most potent inhibitor among a group of several acyclopyrimidine nucleosides, with a K i (measured against the intestinal tissue homogenate, which contained both TP and UP) of 0.36 mM in human, 0.94 mM in rabbit, 0.0097 mM in rat and 0.0176 mM in mouse. Niedzwicki and co-workers [160] also reported a study of 87 pyrimidine base or nucleoside analogues as potential inhibitors of both TP and UP, which resulted in the development of structure-activity relationships that are useful in the rational design of more potent inhibitors. That study showed 5-bromouracil to be the most potent inhibitor of TP, with a K i of 33 µM, and 5-benzyloxybenzylacyclouridine to be the most potent inhibitor of UP, with a K i of 0.17 µM [160] . A study [161] that used the structure of E. coli TP to rationally design a series of 5-substituted 6-aminouracils and 7-substituted pyrrolo [2,3- . The limited success in developing effective TP inhibitors and in formulating accurate structureactivity relationships may be due, in part, to the lack of a detailed structural model from the NP-II family in its active closed conformation. Our recent structural studies of PyNP provide a model for the closed conformation, and may prove valuable to the structure-based drug design efforts to produce potent inhibitors.
CONCLUDING REMARKS
The NP-I and NP-II families represent two structurally distinct families of enzymes that catalyse the same fundamental biochemical reaction. These families represent the only two folds known to be involved in the phosphorolysis of a wide range of purine and pyrimidine nucleosides. Analysis of the sequences of members of the NP-I family in combination with the known three-dimensional structures has revealed regions of the NP-I fold that may account for the differences in substrate specificity and in quaternary structure among family members. Detailed structural analyses have provided significant information concerning the structure-function relationships in both of these families, and help to explain the differences and similarities that exist among their respective members. While the folds of the NP-I and NP-II families are not related, the arrangement of substrates in the active sites and the conformation of the bound nucleosides show striking similarities. In addition, although the catalytic mechanism of TP has not been studied to the extent of that of PNP, it is likely to be very similar to that proposed for the NP-I family. The NP-I and NP-II families provide a clear example of two distinct enzyme families that show similar substrate specificity and probably employ a similar catalytic mechanism while also maintaining distinct three-dimensional folds. Despite the similarity of the reactions catalysed in these two families, the uniqueness of their respective folds suggests that they have evolved independently. Information concerning structurefunction relationships in these families suggests possible evolutionary pathways, and is also valuable as the search for clinically useful inhibitors continues.
